Currently, immune checkpoint inhibitors are investigated in the neoadjuvant setting in OCSCC, and this could allegedly enhance CD8+ T-cell activity and reverse tumor host interplay, thus reducing also the risk of tumor escape at distant sites [64,65,66,67,68]. The gene discussed is CD8A; the disease is neoplasm.